

Supplemental Table for:

Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial
Alon Kahana et al.

Supplemental Table 1. Summary of VAWS Data			
Component	Points	Count*	Percentage
Globe Intact	20	167	100.0
	0	2	1.2
VA vs. baseline	5	165	98.8
	0	11	6.6
VA vs. 20/200	5	156	93.4
	0	8	4.8
No Diplopia	2	159	95.2
	0	19	11.4
Fusion	2	148	88.6
	0	61	36.5
No Tearing	3	106	63.5
	0	63	37.7
Lacrimal Intact	3	104	62.3
	0	12	7.2
	5	20	12.0
Satisfaction	10	135	80.8

*indicates the number of occurrences of this result across all patients and all timepoints.